Keyword: Spectrum Pharmaceuticals
Eisai's stock plummets at AD failure; Keytruda has much upside in China, analysts say; Korea Exchange is dragged into Samsung accounting probe.
Spectrum Pharmaceuticals has pulled its biologics license application for Rolontis because the FDA needs more CMC information.
Terns names ex-Gilead executive as CMO; Spectrum sells all FDA-approved drugs to Aurobindo; Aslan's varlitinib fails in gastric cancer.
Spectrum is offloading seven drugs and transferring 40% of its total workforce to Aurobindo in a deal to "laser-focus" on novel cancer drugs.
Spectrum Pharma—a rare disease and cancer specialist with six marketed drugs and $116 million in annual sales—is eyeing a sale, Bloomberg says.